omeprazol capsule 20 mg
lekpharm srl - omeprazolum - capsule - 20 mg
cedax capsule 400 mg
schering-plough central east ag - ceftibutenum - capsule - 400 mg
cedax pulbere pentru suspensie orala 36 mg/ml
schering-plough central east ag - ceftibutenum - pulbere pentru suspensie orala - 36 mg/ml
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
tratul plus
lannacher heilmittel ges.m.b.h. - austria - combinatii (diclofenacum+thiaminum+pyridoxinum+cyanocobalaminum) - caps. gastrorez. - antiinflamatoare si antireumatice nesteroidiene derivati ai acidului acetic si substante inrudite
clodifen picaturi oftalmice, solutie 1 mg/ml
world medicine ophthalmics - diclofenacum - picaturi oftalmice, solutie - 1 mg/ml
alactin comprimate 0,5 mg
teva pharmaceutical industries ltd - cabergolinum - comprimate - 0,5 mg
fersinol-z capsule
world medicine limited - combinaţie - capsule
floximed unguent oftalmic 3 mg/g
world medicine ophthalmics - ciprofloxacinum - unguent oftalmic - 3 mg/g
floximed picaturi oftalmice, solutie 0,3%
world medicine ophthalmics - ciprofloxacinum - picaturi oftalmice, solutie - 0,3%